haloperidol has been researched along with Ambulation Disorders, Neurologic in 11 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prodromal subjects and unmedicated patients with first-episode schizophrenia showed significant PPI deficits, whereas schizophrenia patients treated with risperidone had almost normal PPI." | 5.13 | Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia. ( Berning, J; Frommann, I; Kühn, KU; Maier, W; Quednow, BB; Wagner, M, 2008) |
| "The apomorphine treatments given to the vehicle group generated a progressive locomotion sensitization effect and this effect was potentiated by pre-exposure to 0." | 1.38 | Opposite effects of low versus high dose haloperidol treatments on spontaneous and apomorphine induced motor behavior: evidence that at a very low dose haloperidol acts as an indirect dopamine agonist. ( Carey, RJ; Carrera, MP; de Matos, LW; Dias, FR; Sampaio, Mde F, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tournier, BB | 1 |
| Ginovart, N | 1 |
| Quednow, BB | 1 |
| Frommann, I | 1 |
| Berning, J | 1 |
| Kühn, KU | 1 |
| Maier, W | 1 |
| Wagner, M | 1 |
| Gillespie, RJ | 1 |
| Bamford, SJ | 1 |
| Botting, R | 1 |
| Comer, M | 1 |
| Denny, S | 1 |
| Gaur, S | 1 |
| Griffin, M | 1 |
| Jordan, AM | 1 |
| Knight, AR | 1 |
| Lerpiniere, J | 1 |
| Leonardi, S | 1 |
| Lightowler, S | 1 |
| McAteer, S | 1 |
| Merrett, A | 1 |
| Misra, A | 1 |
| Padfield, A | 1 |
| Reece, M | 1 |
| Saadi, M | 1 |
| Selwood, DL | 1 |
| Stratton, GC | 1 |
| Surry, D | 1 |
| Todd, R | 1 |
| Tong, X | 1 |
| Ruston, V | 1 |
| Upton, R | 1 |
| Weiss, SM | 1 |
| Koch, HJ | 1 |
| Nanev, D | 1 |
| Becker, K | 1 |
| Dias, FR | 1 |
| de Matos, LW | 1 |
| Sampaio, Mde F | 1 |
| Carey, RJ | 1 |
| Carrera, MP | 1 |
| Feifel, D | 2 |
| Melendez, G | 1 |
| Shilling, PD | 1 |
| Lebsanft, HB | 1 |
| Kohles, T | 1 |
| Kovar, KA | 1 |
| Schmidt, WJ | 1 |
| Kelly, MP | 1 |
| Isiegas, C | 1 |
| Cheung, YF | 1 |
| Tokarczyk, J | 1 |
| Yang, X | 1 |
| Esposito, MF | 1 |
| Rapoport, DA | 1 |
| Fabian, SA | 1 |
| Siegel, SJ | 1 |
| Wand, G | 1 |
| Houslay, MD | 1 |
| Kanes, SJ | 1 |
| Abel, T | 1 |
| Hadamitzky, M | 1 |
| Harich, S | 1 |
| Koch, M | 1 |
| Schwabe, K | 1 |
| Wang, Y | 1 |
| Xu, R | 1 |
| Sasaoka, T | 1 |
| Tonegawa, S | 1 |
| Kung, MP | 1 |
| Sankoorikal, EB | 1 |
| Priebe, K | 1 |
1 trial available for haloperidol and Ambulation Disorders, Neurologic
| Article | Year |
|---|---|
Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia.
Topics: Acoustic Stimulation; Adult; Analysis of Variance; Antipsychotic Agents; Case-Control Studies; Femal | 2008 |
10 other studies available for haloperidol and Ambulation Disorders, Neurologic
| Article | Year |
|---|---|
Repeated but not acute treatment with ∆⁹-tetrahydrocannabinol disrupts prepulse inhibition of the acoustic startle: reversal by the dopamine D₂/₃ receptor antagonist haloperidol.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Antagonists; D | 2014 |
Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines.
Topics: Adenosine A2 Receptor Antagonists; Amines; Animals; Azoles; Drug Design; Drug Evaluation, Preclinica | 2009 |
[Acute behaviour disorder in a patient with X-linked hydrocephalus with normal pressure].
Topics: Antipsychotic Agents; Bisoprolol; Dementia; Drug Therapy, Combination; Gait Disorders, Neurologic; G | 2009 |
Opposite effects of low versus high dose haloperidol treatments on spontaneous and apomorphine induced motor behavior: evidence that at a very low dose haloperidol acts as an indirect dopamine agonist.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Apomorphine; Dopamine Agonists; Dose-Response R | 2012 |
Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects.
Topics: Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Dose-Response Relationship, Drug; | 2004 |
3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy.
Topics: Adrenergic Uptake Inhibitors; Animals; Antiparkinson Agents; Behavior, Animal; Catalepsy; Denervatio | 2005 |
Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP.
Topics: Acoustic Stimulation; Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; | 2007 |
Deficient prepulse inhibition induced by selective breeding of rats can be restored by the dopamine D2 antagonist haloperidol.
Topics: Acoustic Stimulation; Animals; Behavior, Animal; Breeding; Clozapine; Dopamine Antagonists; Female; | 2007 |
Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions.
Topics: Animals; Anxiety; Behavior, Animal; Catalepsy; Corpus Striatum; Dopamine Agonists; Dopamine Antagoni | 2000 |
Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Drug Administration Schedule; Gait Disorders, Ne | 2001 |